{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T07:52:26Z","timestamp":1789631546604,"version":"build-2803163510"},"reference-count":41,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T00:00:00Z","timestamp":1763596800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Advanced gastric\/gastroesophageal junction (G\/GEJ) adenocarcinoma remains a common and deadly form of cancer. Advances in G\/GEJ cancer treatment have improved survival outcomes with the claudin-18.2 (CLDN18.2)-targeted agent, zolbetuximab, and immune checkpoint inhibitors (ICIs) targeting the PD-1 receptor. This article offers an evidence-informed opinion on considerations when selecting between these first-line treatments for G\/GEJ adenocarcinoma in patients with HER2-negative disease that expresses CLDN18.2 and\/or PD-L1, including the reliability of biomarker scoring and interpretation, overall survival (OS) rates, toxicity profiles, and logistical practicalities. Evidence from Phase III trials for zolbetuximab and ICIs suggest similar OS benefits of 14\u201318 months compared to chemotherapy alone, but there appears to be a gradient of benefit for ICIs with increasing PD-L1 combined positive score (CPS). There is high inter-observer variability in CPS scoring, particularly at lower thresholds. Zolbetuximab is associated with high rates of nausea and vomiting during the initial infusion, whereas ICIs are associated with risk of later-onset immune-related toxicities that can be fatal in rare cases. In considering the available evidence, our opinion is that zolbetuximab is a reasonable option for initial targeted treatment in HER2-\/CLDN18.2-positive advanced G\/GEJ when PD-L1 CPS score is &lt;10 based on the reliability of biomarker testing, comparable OS, and avoidance of potentially irreversible ICI-induced immune toxicity.<\/jats:p>","DOI":"10.3390\/curroncol32110648","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T10:30:59Z","timestamp":1763634659000},"page":"648","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Zolbetuximab or Immunotherapy as the Initial Targeted Therapy in CLDN18.2-Positive, HER2-Negative Advanced Gastric Cancer: Weighing the Options"],"prefix":"10.3390","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5270-1050","authenticated-orcid":false,"given":"Jacob C.","family":"Easaw","sequence":"first","affiliation":[{"name":"Faculty of Medicine & Dentistry, Department of Oncology, University of Alberta, Edmonton, AB T6G 2R3, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard J.","family":"Lim","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Faculty of Medicine, University of British Columbia and Systemic Therapy BC Cancer, Vancouver, BC V5Z 4E6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hatim","family":"Karachiwala","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Arthur J.E. Child Comprehensive Cancer Center, Calgary, AB T2N 5G2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3306-3617","authenticated-orcid":false,"given":"Sharlene","family":"Gill","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Faculty of Medicine, University of British Columbia and Systemic Therapy BC Cancer, Vancouver, BC V5Z 4E6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofu","family":"Zhu","sequence":"additional","affiliation":[{"name":"Faculty of Medicine & Dentistry, Department of Oncology, University of Alberta, Edmonton, AB T6G 2R3, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Bateman","sequence":"additional","affiliation":[{"name":"Faculty of Medicine & Dentistry, Laboratory Medicine & Pathology Department, University of Alberta, Edmonton, AB T6G 1C9, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,11,20]]},"reference":[{"key":"ref_1","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA A Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"883","DOI":"10.3332\/ecancer.2018.883","article-title":"Targeted literature review of the global burden of gastric cancer","volume":"12","author":"Casamayor","year":"2018","journal-title":"Ecancermedicalscience"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): A randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/S1470-2045(23)00515-6","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): A multicentre, randomised, double-blind, phase 3 trial","volume":"24","author":"Rha","year":"2023","journal-title":"Lancet Oncol."},{"key":"ref_5","first-page":"870","article-title":"Comparison of Claudin 18.2 expression in primary tumors and lymph node metastases in Japanese patients with gastric adenocarcinoma","volume":"49","author":"Rohde","year":"2019","journal-title":"Ultrasound Med. Biol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1158\/1078-0432.CCR-13-3141","article-title":"Molecular Pathways: The Immunogenic Effects of Platinum-Based Chemotherapeutics","volume":"20","author":"Hato","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1093\/annonc\/mdz199","article-title":"A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: The MONO study","volume":"30","author":"Sahin","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1007\/s10120-024-01518-1","article-title":"Global prevalence of claudin 18 isoform 2 in tumors of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma","volume":"27","author":"Shitara","year":"2024","journal-title":"Gastric Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1200\/JCO.23.01601","article-title":"First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial","volume":"42","author":"Janjigian","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"4036","DOI":"10.1200\/JCO.2024.42.16_suppl.4036","article-title":"Final overall survival results from phase 3 SPOTLIGHT study evaluating zolbetuximab + mFOLFOX6 as first-line (1L) treatment for patients (pts) with claudin 18 isoform 2 (CLDN18.2)+, HER2\u2212, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG\/GEJ) adenocarcinoma","volume":"42","author":"Shitara","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"S1524","DOI":"10.1016\/j.annonc.2023.10.270","article-title":"134MO Updated efficacy and safety results from phase III GLOW study evaluating zolbetuximab + CAPOX as first-line (1L) treatment for patients with claudin-18 isoform 2-positive (CLDN18.2+), HER2\u2212, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG\/GEJ) adenocarcinoma","volume":"34","author":"Lordick","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Yin, Q., Wu, L., Han, L., Zheng, X., Tong, R., Li, L., Bai, L., and Bian, Y. (2023). Immune-related adverse events of immune checkpoint inhibitors: A review. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1167975"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"352","DOI":"10.4251\/wjgo.v15.i2.352","article-title":"Immune-related adverse events associated with immune checkpoint inhibitors for advanced gastric and gastroesophageal junction cancer: A meta-analysis","volume":"15","author":"Pei","year":"2023","journal-title":"World J. Gastrointest. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update","volume":"39","author":"Schneider","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","article-title":"Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): A multicentre, randomised, double-blind, phase 3 trial","volume":"401","author":"Shitara","year":"2023","journal-title":"Lancet"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1038\/s41591-023-02465-7","article-title":"Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: The randomized, phase 3 GLOW trial","volume":"29","author":"Shah","year":"2023","journal-title":"Nat. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"S895","DOI":"10.1016\/j.annonc.2024.08.1504","article-title":"1438P First-line (1L) zolbetuximab + chemotherapy in patients (pts) with claudin 18.2 (CLDN18.2) +, HER2-, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG\/GEJ) adenocarcinoma: A pooled final analysis of SPOTLIGHT + GLOW","volume":"35","author":"Kang","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"101233","DOI":"10.1016\/j.xcrm.2023.101233","article-title":"SPOTlight on GLOW","volume":"4","author":"Derks","year":"2023","journal-title":"Cell Rep. Med."},{"key":"ref_19","unstructured":"(2025, September 23). VyloyPM. Available online: https:\/\/www.vyloypm.com\/."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1056\/NEJMc2409512","article-title":"Zolbetuximab in Gastric or Gastroesophageal Junction Adenocarcinoma","volume":"391","author":"Shitara","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1200\/JCO.2024.42.3_suppl.372","article-title":"Management of nausea and vomiting (N\/V) following first-line (1L) zolbetuximab + chemotherapy treatment in claudin-18.2 (CLDN18.2)+, HER2\u2212, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG\/GEJ) adenocarcinoma: Analysis from the phase 3 SPOTLIGHT and GLOW studies","volume":"42","author":"Shitara","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"100128","DOI":"10.1016\/j.esmogo.2024.100128","article-title":"Managing zolbetuximab-induced nausea and vomiting: A proposal for a pragmatic approach in clinical practice","volume":"7","author":"Shimozaki","year":"2025","journal-title":"ESMO Gastrointest. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"100131","DOI":"10.1016\/j.esmogo.2024.100131","article-title":"Consensus guidance for prevention and management of nausea and vomiting in patients treated with zolbetuximab + chemotherapy: A RAND\/UCLA modified Delphi panel study","volume":"7","author":"Klempner","year":"2025","journal-title":"ESMO Gastrointest. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.trsl.2024.09.001","article-title":"Diagnostic, prognostic, and predictive biomarkers in gastric cancer: From conventional to novel biomarkers","volume":"274","author":"Rouzbahani","year":"2024","journal-title":"Transl. Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"7770","DOI":"10.3390\/curroncol31120572","article-title":"Canadian Consensus Recommendations for Predictive Biomarker Testing in Gastric and Gastroesophageal Junction Adenocarcinoma","volume":"31","author":"Fiset","year":"2024","journal-title":"Curr. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.3390\/curroncol31050191","article-title":"Best Practices for Managing Patients with Unresectable Metastatic Gastric and Gastroesophageal Junction Cancer in Canada","volume":"31","author":"Snow","year":"2024","journal-title":"Curr. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.annonc.2021.02.005","article-title":"FAST: A randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma","volume":"32","author":"Sahin","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Covert, W.M., and Rogers, J.E. (2025). Future Landscape of Anti-Claudin 18.2 Antibodies in Gastric Adenocarcinoma. Antibodies, 14.","DOI":"10.3390\/antib14010026"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"100284","DOI":"10.1016\/j.labinv.2023.100284","article-title":"Global Ring Study to Investigate the Comparability of Total Assay Performance of Commercial Claudin 18 Antibodies for Evaluation in Gastric Cancer","volume":"104","author":"Jasani","year":"2023","journal-title":"Mod. Pathol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"100128","DOI":"10.1016\/j.modpat.2023.100128","article-title":"Multi-Institutional Study of Pathologist Reading of the Programmed Cell Death Ligand-1 Combined Positive Score Immunohistochemistry Assay for Gastric or Gastroesophageal Junction Cancer","volume":"36","author":"Fernandez","year":"2023","journal-title":"Mod. Pathol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"100154","DOI":"10.1016\/j.modpat.2023.100154","article-title":"High Interobserver Variability Among Pathologists Using Combined Positive Score to Evaluate PD-L1 Expression in Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma","volume":"36","author":"Robert","year":"2023","journal-title":"Mod. Pathol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1097\/PAI.0000000000000800","article-title":"Fit-For-Purpose PD-L1 Biomarker Testing For Patient Selection in Immuno-Oncology: Guidelines For Clinical Laboratories From the Canadian Association of Pathologists-Association Canadienne Des Pathologistes (CAP-ACP)","volume":"27","author":"Cheung","year":"2019","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/s10120-021-01195-4","article-title":"Optimized PD-L1 scoring of gastric cancer","volume":"24","author":"Eschbach","year":"2021","journal-title":"Gastric Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41419-023-06388-6","article-title":"Comparative single-cell analysis reveals heterogeneous immune landscapes in adenocarcinoma of the esophagogastric junction and gastric adenocarcinoma","volume":"15","author":"Chen","year":"2024","journal-title":"Cell Death Dis."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1097\/SLA.0000000000005320","article-title":"Distinct Differences in Gastroesophageal Junction and Gastric Adenocarcinoma in 2194 Patients","volume":"277","author":"Nakauchi","year":"2021","journal-title":"Ann. Surg."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3892\/mi.2024.137","article-title":"Immune checkpoint inhibitors in metastatic melanoma therapy (Review)","volume":"4","author":"Shah","year":"2024","journal-title":"Med. Int."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1007\/s10147-024-02521-3","article-title":"New therapeutic target molecules for gastric and gastroesophageal junction cancer","volume":"29","author":"Kawakami","year":"2024","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Lordick, F., Rha, S.Y., Muro, K., Yong, W.P., and Obermannov\u00e1, R.L. (2024). Systemic Therapy of Gastric Cancer\u2014State of the Art and Future Perspectives. Cancers, 16.","DOI":"10.3390\/cancers16193337"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e012683","DOI":"10.1136\/jitc-2025-012683","article-title":"Dynamic modulation of claudin18.2 expression and remodeling of the tumor microenvironment in gastric cancer during chemo-immunotherapy","volume":"13","author":"Lim","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3882","DOI":"10.1158\/1078-0432.CCR-23-0204","article-title":"ILUSTRO: Phase II Multicohort Trial of Zolbetuximab in Patients with Advanced or Metastatic Claudin 18.2\u2013Positive Gastric or Gastroesophageal Junction Adenocarcinoma","volume":"29","author":"Klempner","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.annonc.2022.07.004","article-title":"Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Lordick","year":"2022","journal-title":"Ann. Oncol."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/11\/648\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T11:15:41Z","timestamp":1763637341000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/11\/648"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,20]]},"references-count":41,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["curroncol32110648"],"URL":"https:\/\/doi.org\/10.3390\/curroncol32110648","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,20]]}}}